logo-loader
viewHemoGenyx Pharmaceuticals

HemoGenyx signs collaboration agreement with Rockefeller University to develop new Lupus treatments

Vladislav Sandler, CEO and co-founder of HemoGenyx, said: “This agreement with Rockefeller has the potential to extend our product candidate opportunities into a new and exciting area, and we would fully expect to see the work funded through future non-dilutive grant funding”

laboratory
The biotechnology company said its directors are confident that the collaboration does not require forms of funding that would be dilutive to HemoGenyx shareholders

HemoGenyx Pharmaceuticals PLC (LON:HEMO) has entered into a collaboration agreement with Rockefeller University to use its new type of humanised mice for autoimmune disease modelling in an effort to develop new treatment for autoimmune diseases, specifically Lupus.

Under the agreement, the collaborative work will be co-led by investigators at HemoGenyx and Rockefeller with professor Alexander Tarakhovsky acting as the principal investigator for Rockefeller and Dr Vladislav Sandler acting as the principal investigator for Hemogenyx.

WATCH: HemoGenyx CEO says progress 'definitely surpassing expectations'

The biotechnology company said its directors are confident that the collaboration does not require forms of funding that would be dilutive to HemoGenyx shareholders.

Vladislav Sandler, CEO and co-founder of HemoGenyx, said: “This agreement with Rockefeller has the potential to extend our product candidate opportunities into a new and exciting area, and we would fully expect to see the work funded through future non-dilutive grant funding.”

He added: ”Shareholders can now also see the potential for the use of our technology beyond our current bone marrow transplantation focus to treat debilitating and otherwise incurable autoimmune diseases such as Lupus.”

HemoGenyx said the first stage of development work will create mice that emulate the human symptoms of Lupus, while the second stage will then focus on the development of multi-specific antibodies and cell therapies to treat the disease in these mice.

Vladislav Sandler said: “The attractiveness of our new type of humanized mice to major biotechnology companies and leading research institutes will give us further opportunities to collaborate on other disease models and specific drug development.”

Quick facts: HemoGenyx Pharmaceuticals

Price: 1.9 GBX

LSE:HEMO
Market: LSE
Market Cap: £7.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

2 min read